CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
ixabepilone +1 moredrug
Likely dose
Ixabepilone 40 mg/m² intravenously once every 3 weeksAI-extracted
Key inclusion· 3
  • ✓Up to three prior chemotherapy regimens allowed
  • ✓Measurable or non-measurable disease
  • ✓Available for treatment and follow-up
Key exclusion· 3
  • ✕Neuropathy
  • ✕Uncontrolled cardiovascular disease
  • ✕Refusal to participate in genetic analysis

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00207090
NCT00207090Phase 1Completed
CompareCT.gov

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

R-Pharm·interventional·Posted Sep 21, 2005·Updated Nov 2, 2020

In Brief

A Phase 1 clinical trial evaluating ixabepilone and Rifampin for Advanced Solid Tumors and Neoplasms. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors, Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartSep 1, 2005
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 20.8 years ago

Interventions

ixabepilonedrug

ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression

Rifampindrug

rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2